April 11th 2024
The FDA’s fast track designation of LYT-200 in this population is supported by an ongoing phase 1/2 clinical trial.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Novel CAR T-Cell Therapies to Come From Amgen/Kite Pharma Collaboration
January 6th 2015Amgen and Kite Pharma have announced that they will collaborate on the development of novel CAR T-cell immunotherapies, with Amgen providing cancer targets and Kite offering its engineered autologous cell therapy platform.
Read More
CAR T-Cell Therapy CTL019 Demonstrates 92% Response Rate in Pediatric ALL
December 7th 2014The anti-CD19 chimeric antigen receptor (CAR)-modified T-cell therapy CTL019 demonstrated a 92% complete response (CR) rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (ALL).
Read More
Future Looks Promising for Immunotherapy in Head and Neck Cancer
November 7th 2014Both HPV-positive and -negative head and neck cancers are “outstanding candidates for immunotherapeutic strategies,†said Andrew G. Sikora, MD, PhD, Baylor College of Medicine, at the 2014 Chemotherapy Foundation Symposium.
Read More
Afatinib Improves PFS in Advanced Head and Neck Cancer
September 29th 2014Afatinib delayed disease progression for approximately one month longer than chemotherapy and helped prevent painful symptoms from worsening for patients with relapsed or metastatic head and neck squamous cell carcinoma.
Read More
Thyroid Cancer: Targeted Agents Show Promise Following Radioactive Iodine Resistance
August 28th 2014A better understanding of the molecular pathways that confer resistance to RAI in the treatment of differentiated thyroid cancer has led to success in targeting the VEGF and the VEGF receptor pathways.
Read More
First FDA Breakthrough Designation Granted to CAR Therapy
July 11th 2014The investigational CD19-targeted chimeric antigen receptor (CAR) therapy CTL019 has received a breakthrough therapy designation from the FDA as a potential treatment for pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL).
Read More
An Analysis of the Results of the SELECT Trial in Thyroid Cancer
June 12th 2014Lori J. Wirth, MD, discusses the results from the phase III SELECT trial that analyzed lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer. There were 6 treatment-related deaths on the study.
Watch